UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed	l by the	e Registrant ⊠	Filed by a Party other than the Registrant \Box	
Chec	k the a	appropriate box:		
	Preli	minary Proxy Statement		
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
	Defii	nitive Proxy Statement		
X	Defii	nitive Additional Materials		
	Solic	iting Material Pursuant to §	240.14a-12	
		A	LDEYRA THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter)	
			(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Payn	nent of	Filing Fee (Check the appro	opriate box):	
X	No fee required.			
	Fee o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class of secur	ities to which transaction applies:	
	(2)	Aggregate number of secu	rities to which transaction applies:	
	(3)	Per unit price or other und fee is calculated and state	erlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing now it was determined):	
	(4)	Proposed maximum aggre	gate value of transaction:	
	(5)	Total fee paid:		
		\$		
	Fee paid previously with preliminary materials.			
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.			
	(1)	Amount Previously Paid:		

Form, Schedule or Registration Statement No.:

(3)	Filing Party:
(4)	Date Filed:

91615

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 8, 2017.

ALDEYRA THERAPEUTICS, INC.

noting Type. Appual Mosting

Meeting Type: Annual Meeting For holders as of: April 13, 2017

Date: June 8, 2017 Time: 10:00 AM, EDT
Location: Offices of Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP
One Marina Park Drive, Suite 900

Boston, MA 02210

ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVE. LEXINGTON, MA 02421 You are receiving this communication because you hold shares in the company named above.

Meeting Information

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT FORM 10-K

How to View Online:

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) *BY INTERNET*: www.proxyvote.com 2) *BY TELEPHONE*: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** | If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** | If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** | If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

** | If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow |

** | If requesting materials | If req

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 25, 2017 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

1.

The Board of Directors recommends you vote FOR the following:

Voting items

1. Election of Two Class III Directors

Nominees

- 01) Todd C. Brady, M.D., Ph.D.
- 02) Martin J. Joyce

The Board of Directors recommends you vote FOR proposal 2.

2. To ratify the appointment of BDO USA, LLP as Aldeyra Therapeutics, Inc.'s independent registered public accounting firm for the year ending December 31, 2017.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.